AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24744152 — intervention group
Group type: COMPARATOR
Intervention: High-dose (HD) intravenous cyclophosphamide (CYC) - 6 monthly pulses followed by two quarterly pulses at 0.5-1.0 g/m(2)
Number of subjects: 225
Study 22113951 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (60 mg every 6 months) - long-term group
Number of subjects: 4550
Study 22113951 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (60 mg every 6 months) - cross-over group
Number of subjects: 4550
Study 22113951 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (60 mg every 6 months) - both groups
Number of subjects: 4550
Study 19917652 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker assessments and referrals for sick newborns
Number of subjects: 10006
Study 19917652 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment by CHWs before death
Number of subjects: 10006
Study 19134277 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG (OPCAB)
Number of subjects: 849
Study 19134277 — intervention group
Group type: COMPARATOR
Intervention: On-pump CABG (CCAB)
Number of subjects: 849
Study 15941900 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein supplement (42 g protein, 24 g carbohydrate, 2 g fat)
Number of subjects: 51
Study 15941900 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate supplement (70 g carbohydrate)
Number of subjects: 51
Study 15941900 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein supplement
Number of subjects: 51
Study 14571155 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient educational compliance enhancing programme (CP)
Number of subjects: 1031
Study 14571155 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 1031
Study 14571155 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall adherence (measured by questioning, measurable serum levels, appointments kept, composite index)
Number of subjects: 1031
Study 10739728 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense insulin treatment
Number of subjects: 620
Study 10739728 — intervention group
Group type: COMPARATOR
Intervention: Standard antidiabetic therapy
Number of subjects: 620
Study 8640038 — intervention group
Group type: EXPERIMENTAL
Intervention: G985 mutation in medium-chain acyl-CoA dehydrogenase gene
Number of subjects: 2000
Study 8640038 — intervention group
Group type: COMPARATOR
Intervention: Infants dead from sudden infant death syndrome
Number of subjects: 2000
Study 8640038 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-chain acyl-CoA dehydrogenase deficiency incidence
Number of subjects: 2000
Study 1720217 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprenolol
Number of subjects: 25
Study 1720217 — intervention group
Group type: COMPARATOR
Intervention: Phentolamine
Number of subjects: 25
Study 1720217 — intervention group
Group type: COMPARATOR
Intervention: Trimethaphan camsilate
Number of subjects: 25
Study 6131148 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (4 mg intravenously)
Number of subjects: 78
Study 6131148 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (10 mg intravenously)
Number of subjects: 78
Study 6131148 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 78
Study 6131148 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 78
Study 31202919 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie summation condition (access to automatically updating calorie information)
Number of subjects: 0
Study 31202919 — intervention group
Group type: COMPARATOR
Intervention: No calorie summation condition (no access to automatically updating calorie information)
Number of subjects: 0
Study 31202919 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie summation condition
Number of subjects: 0
Study 29754649 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacist specialist‐delivered telehealth intervention
Number of subjects: 428
Study 29754649 — intervention group
Group type: COMPARATOR
Intervention: Education control group
Number of subjects: 428
Study 26702926 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir plus darunavir/ritonavir
Number of subjects: 805
Study 26702926 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir/emtricitabine plus darunavir/ritonavir
Number of subjects: 805
Study 25224019 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydrated human amnion/chorion membrane allograft and multilayer compression therapy
Number of subjects: 84
Study 25224019 — intervention group
Group type: COMPARATOR
Intervention: Multilayer compression therapy alone
Number of subjects: 84
Study 22763903 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP block (20 mL 0.5% ropivacaine)
Number of subjects: 80
Study 22763903 — intervention group
Group type: COMPARATOR
Intervention: Placebo blocks
Number of subjects: 80
Study 20231645 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard informed consent with detailed informational aids
Number of subjects: 34
Study 20231645 — intervention group
Group type: COMPARATOR
Intervention: Standard informed consent without detailed informational aids (Control)
Number of subjects: 34
Study 17911647 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B (AmB) treatment
Number of subjects: 0
Study 17911647 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium antimony gluconate (SAG) treatment
Number of subjects: 0
Study 17911647 — intervention group
Group type: EXPERIMENTAL
Intervention: Cure from VL
Number of subjects: 0
Study 17911647 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune responses in PKDL patients
Number of subjects: 0
Study 15642816 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for subfoveal choroidal neovascularization
Number of subjects: 225
Study 15642816 — intervention group
Group type: COMPARATOR
Intervention: Observation for subfoveal choroidal neovascularization
Number of subjects: 225
Study 12364969 — intervention group
Group type: EXPERIMENTAL
Intervention: Anal submucosal injection (ASI) of amikacin 400 mg daily for ten times
Number of subjects: 50
Study 12364969 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular injection (IM) of amikacin 400 mg daily for ten times
Number of subjects: 50
Study 12364969 — intervention group
Group type: EXPERIMENTAL
Intervention: ASI group
Number of subjects: 50
Study 12364969 — intervention group
Group type: COMPARATOR
Intervention: IM group
Number of subjects: 50
Study 9989373 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 16
Study 9989373 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 16
Study 9989373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7584917 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg isosorbide‐5‐mononitrate
Number of subjects: 141
Study 7584917 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg isosorbide‐5‐mononitrate
Number of subjects: 141
Study 7584917 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg isosorbide‐5‐mononitrate
Number of subjects: 141
Study 7584917 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 141
Study 2142577 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic desogestrel (150/30)
Number of subjects: 0
Study 2142577 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic desogestrel
Number of subjects: 0
Study 2142577 — intervention group
Group type: COMPARATOR
Intervention: Monophasic levonorgestrel (150/30)
Number of subjects: 0
Study 2142577 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic desogestrel (150/20)
Number of subjects: 0
Study 2142577 — intervention group
Group type: EXPERIMENTAL
Intervention: All preparations
Number of subjects: 0
Study 2142577 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic desogestrel (150/30) and biphasic desogestrel
Number of subjects: 0
Study 498765 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg tetraethylthiuramdisulfide (Antabuse) two to four times daily for 4-10 weeks
Number of subjects: 11
Study 498765 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment discontinuation
Number of subjects: 11
Study 498765 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effects of Antabuse treatment
Number of subjects: 11
Study 498765 — intervention group
Group type: EXPERIMENTAL
Intervention: Nickel levels during treatment
Number of subjects: 11
Study 30845329 — intervention group
Group type: EXPERIMENTAL
Intervention: Vi‐TCV vaccine
Number of subjects: 20000
Study 30845329 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine
Number of subjects: 20000
Study 28483503 — intervention group
Group type: COMPARATOR
Intervention: REI‐ObGyn
Number of subjects: 630
Study 28483503 — intervention group
Group type: COMPARATOR
Intervention: ObGyn
Number of subjects: 630
Study 28483503 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle changes recommendation
Number of subjects: 630
Study 25636048 — intervention group
Group type: EXPERIMENTAL
Intervention: Parathyroidectomy (PTX)
Number of subjects: 191
Study 25636048 — intervention group
Group type: COMPARATOR
Intervention: Observation (OBS)
Number of subjects: 191
Study 23460234 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk fortified with 600 IU (15 μg) of vitamin D per day for 12 weeks
Number of subjects: 713
Study 23460234 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk fortified with 1,000 IU (25 μg) of vitamin D per day for 12 weeks
Number of subjects: 713
Study 23460234 — intervention group
Group type: COMPARATOR
Intervention: Unfortified milk (control group) 200 ml per day for 12 weeks
Number of subjects: 713
Study 21280197 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX 1 g/m² in 24 hr with intrathecal injection
Number of subjects: 352
Study 21280197 — intervention group
Group type: COMPARATOR
Intervention: MTX 3 g/m² in 3 hr without intrathecal
Number of subjects: 352
Study 21280197 — intervention group
Group type: EXPERIMENTAL
Intervention: Courses with vinblastine
Number of subjects: 352
Study 21280197 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 352
Study 19843421 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate antibiotics
Number of subjects: 807
Study 19843421 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed antibiotics
Number of subjects: 807
Study 19843421 — intervention group
Group type: EXPERIMENTAL
Intervention: No antibiotics
Number of subjects: 807
Study 19843421 — intervention group
Group type: COMPARATOR
Intervention: Information leaflet
Number of subjects: 807
Study 16776933 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/d
Number of subjects: 92
Study 16776933 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg/d
Number of subjects: 92
Study 14647254 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor vaccination on day -20, recipient vaccination on days -1, +50, and +365 (D(-20)R(-1,50,365))
Number of subjects: 85
Study 14647254 — intervention group
Group type: EXPERIMENTAL
Intervention: Recipient vaccination on days -1, +50, and +365 (D(N)R(-1,50,365))
Number of subjects: 85
Study 14647254 — intervention group
Group type: COMPARATOR
Intervention: Recipient vaccination on day +365 (D(N)R(365))
Number of subjects: 85
Study 14647254 — intervention group
Group type: EXPERIMENTAL
Intervention: Recipient immunization on days -1 and 50
Number of subjects: 85
Study 14647254 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor vaccination on day -20
Number of subjects: 85
Study 11575522 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Foley catheter (hole-end catheter)
Number of subjects: 72
Study 11575522 — intervention group
Group type: COMPARATOR
Intervention: Foley catheter
Number of subjects: 72
Study 9754589 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril treatment
Number of subjects: 9
Study 9754589 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 9
Study 7836943 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin‐induced extracorporeal low‐density lipoprotein/fibrinogen precipitation (HELP)
Number of subjects: 0
Study 3286287 — intervention group
Group type: EXPERIMENTAL
Intervention: Sperm incubated in medium containing 20% serum with antisperm activity (Test)
Number of subjects: 17
Study 3286287 — intervention group
Group type: COMPARATOR
Intervention: No antisperm activity (Control)
Number of subjects: 17
Study 31542640 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy regimens (specific regimens not detailed)
Number of subjects: 1654
Study 31065133 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical Muscle Stimulation
Number of subjects: 60
Study 31065133 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (Control)
Number of subjects: 60
Study 26872450 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal Immunochemical Test (FIT)
Number of subjects: 200
Study 26872450 — intervention group
Group type: COMPARATOR
Intervention: Faecal Occult Blood Test (FOBT)
Number of subjects: 200
Study 24821891 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive multimedia computer program (IMCP) tailored to colorectal cancer screening
Number of subjects: 1164
Study 24821891 — intervention group
Group type: COMPARATOR
Intervention: Nontailored informational program (control)
Number of subjects: 1164
Study 24821891 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive multimedia computer program (IMCP)
Number of subjects: 1164
Study 24821891 — intervention group
Group type: COMPARATOR
Intervention: IMCP vs Control
Number of subjects: 1164
Study 23185280 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amantadine (400 mg/day)
Number of subjects: 10
Study 23185280 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 10
Study 23185280 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine tablet (open-label follow-up)
Number of subjects: 10
Study 21302486 — intervention group
Group type: EXPERIMENTAL
Intervention: Fengshikang (FSK) combined with glucocorticoid therapy
Number of subjects: 38
Study 21302486 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) with glucocorticoid therapy
Number of subjects: 38
Study 21302486 — intervention group
Group type: COMPARATOR
Intervention: Normal control group (healthy subjects)
Number of subjects: 38
Study 17351951 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with epirubicin, paclitaxel, and cyclophosphamide plus darbepoetin alpha
Number of subjects: 101
Study 15466946 — intervention group
Group type: EXPERIMENTAL
Intervention: Oats (60 g oatmeal)
Number of subjects: 30
Study 15466946 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU) plus Vitamin C (500 mg)
Number of subjects: 30
Study 15466946 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of oats and vitamins
Number of subjects: 30
Study 15466946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10837840 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated beverages (tea and coffee with 37.5 mg and 75 mg caffeine in tea, 75 mg and 150 mg caffeine in coffee)
Number of subjects: 32
Study 10837840 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated beverages (with varying caffeine levels: 0, 25, 50, 100, and 200 mg)
Number of subjects: 32
Study 10837840 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated beverages
Number of subjects: 32
Study 10837840 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 32
Study 9205202 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined irradiation and operation
Number of subjects: 0
Study 9205202 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation alone
Number of subjects: 0
Study 8403296 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator (rt-PA) infusion
Number of subjects: 2885
Study 8403296 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy with appropriate supplemental measures
Number of subjects: 2885
Study 3096767 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate
Number of subjects: 200
Study 3096767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 3131404 — intervention group
Group type: EXPERIMENTAL
Intervention: gallopamil (10 mg)
Number of subjects: 9
Study 3131404 — intervention group
Group type: EXPERIMENTAL
Intervention: cromolyn sodium (20 mg)
Number of subjects: 9
Study 3131404 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study 3131404 — intervention group
Group type: COMPARATOR
Intervention: control
Number of subjects: 9
Study 31237053 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 hours or longer per day working hours among males with the highest household income
Number of subjects: 11602
Study 31237053 — intervention group
Group type: COMPARATOR
Intervention: Low household income males
Number of subjects: 11602
Study 28370389 — intervention group
Group type: EXPERIMENTAL
Intervention: VSX-objective refraction (optimised using visual Strehl ratio)
Number of subjects: 20
Study 28370389 — intervention group
Group type: COMPARATOR
Intervention: Subjective refraction
Number of subjects: 20
Study 28370389 — intervention group
Group type: EXPERIMENTAL
Intervention: VSX-objective refraction
Number of subjects: 20
Study 26464454 — intervention group
Group type: EXPERIMENTAL
Intervention: THC (Δ9-tetrahydrocannabinol) administered intravenously
Number of subjects: 78
Study 26464454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 23390362 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (6-month, twice weekly)
Number of subjects: 44
Study 21472530 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative pain assessment using Visual Analogic Scale (VAS)
Number of subjects: 0
Study 21472530 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum cytokine assay for interleukin‐6 (IL6)
Number of subjects: 0
Study 21472530 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum cytokine assay for interleukin‐1 (IL1)
Number of subjects: 0
Study 21472530 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum cytokine assay for tumor necrosis factor‐alpha (TNF‐alpha)
Number of subjects: 0
Study 18058656 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsule endoscopy
Number of subjects: 98
Study 18058656 — intervention group
Group type: COMPARATOR
Intervention: Esophagogastroduodenoscopy (EGD)
Number of subjects: 98
Study 16551312 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider reminder
Number of subjects: 311
Study 16551312 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider reminder plus patient education
Number of subjects: 311
Study 16551312 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 311
Study 15273108 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibacterial cleaning products (0.2% triclosan)
Number of subjects: 0
Study 15273108 — intervention group
Group type: COMPARATOR
Intervention: Nonantibacterial cleaning products
Number of subjects: 0
Study 11174445 — intervention group
Group type: EXPERIMENTAL
Intervention: MPEG-1
Number of subjects: 20
Study 11174445 — intervention group
Group type: COMPARATOR
Intervention: sVHS
Number of subjects: 20
Study 9640082 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-beta-D-glucosaminidase (NAG) urine activity in patients with chronic renal failure
Number of subjects: 63
Study 9640082 — intervention group
Group type: EXPERIMENTAL
Intervention: NAG urine activity in patients with massive proteinuria (> 1.5 g/24 h)
Number of subjects: 63
Study 9640082 — intervention group
Group type: EXPERIMENTAL
Intervention: NAG urine activity in patients with moderate proteinuria
Number of subjects: 63
Study 9640082 — intervention group
Group type: EXPERIMENTAL
Intervention: NAG urine activity in patients without 24 hour proteinuria or non-significant proteinuria
Number of subjects: 63
Study 9640082 — intervention group
Group type: EXPERIMENTAL
Intervention: NAG values above and below 280 nmol/mg of creatinine
Number of subjects: 63
Study 9640082 — intervention group
Group type: EXPERIMENTAL
Intervention: NAG values higher than 280 nmol/mg of creatinine
Number of subjects: 63
Study 8278671 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse prevention program
Number of subjects: 120
Study 8278671 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcement program
Number of subjects: 120
Study 8278671 — intervention group
Group type: COMPARATOR
Intervention: Exercise-only control group
Number of subjects: 120
Study 8278671 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 120
Study 3552920 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy
Number of subjects: 112
Study 3552920 — intervention group
Group type: COMPARATOR
Intervention: Splenorenal shunt
Number of subjects: 112
Study 29542334 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-biologic treatment plans (glucocorticoids alone and methotrexate)
Number of subjects: 200
Study 29542334 — intervention group
Group type: COMPARATOR
Intervention: Biologic treatment plans (interleukin-1 blockade and interleukin-6 blockade)
Number of subjects: 200
Study 29542334 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Reported Outcomes Measurement Information System measures
Number of subjects: 200
Study 29542334 — intervention group
Group type: EXPERIMENTAL
Intervention: Other parent-/patient-reported outcomes
Number of subjects: 200
Study 28599712 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.65-g alcohol dose/kg body weight
Number of subjects: 75
Study 28599712 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 75
Study 28599712 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 75
Study 26534969 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (400 mg for 90 days)
Number of subjects: 41
Study 26534969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 26534969 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 41
Study 23109251 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 797
Study 23109251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 797
Study 21074021 — intervention group
Group type: EXPERIMENTAL
Intervention: Carraguard
Number of subjects: 400
Study 21074021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 18556101 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based health education intervention
Number of subjects: 1892